GLP-1 Prescribing Lags Among Adults With Schizophrenia & Diabetes

From 2018 through 2024, adults with serious mental illness (SMI) were more likely than adults without SMI to receive a prescription for a glucagon-like peptide-1 (GLP-1) receptor agonist. However, among adults with diabetes, those with schizophrenia were less likely to receive a GLP-1 prescription than those without SMI. For the research, SMI was defined as schizophrenia, bipolar disorder, or major depressive disorder (MDD).

Across the seven-year period, 5.4% of adults with SMI received any GLP-1 prescription, compared with 2.1% of adults without SMI. Among adults with a GLP-1-indicating condition, prescribing . . .